STOCK TITAN

Takeda Pharmaceutical Company (TAK) Stock News, Apr-Jun 2022

TAK NYSE

Takeda Pharmaceutical Company Limited reports news as a Japan-based, R&D-driven biopharmaceutical company whose American depositary shares trade under TAK. Its updates center on medicines and pipeline programs in gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines, including ENTYVIO, GAMMAGARD LIQUID ERC, HYQVIA, TAK-881, zasocitinib, rusfertide and oveporexton.

Recurring developments include pivotal clinical trial data, U.S. FDA regulatory actions involving new drug applications, prescription product availability, collaboration updates, and financial reports. Takeda also reports on launch preparation, generic competition affecting established products, operating-cost discipline, foreign-exchange effects, corporate transformation initiatives and governance matters tied to its global pharmaceutical business.

Rhea-AI Summary

Takeda reported positive results from the Phase 3 SPRING study of TAKHZYRO, a treatment for hereditary angioedema (HAE) in children aged 2 to 12 years. The study demonstrated a in HAE attacks over 52 weeks compared to baseline. Notably, 76.2% of patients were attack-free during the treatment, with an average of 99.5% attack-free days. The results align with the efficacy and safety profile seen in adults. Takeda plans to initiate global regulatory filings in fiscal year 2022 to expand TAKHZYRO's indication for younger patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
-
Rhea-AI Summary

Takeda (TAK) and Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced promising results from the Phase 2 AROAAT-2002 study of fazirsiran for liver disease due to alpha-1 antitrypsin deficiency (AATD). Key findings include a 58% fibrosis regression in treated patients, an 83% median reduction in Z-AAT accumulation in the liver, and a 69% reduction in histologic globule burden. Fazirsiran aims to tackle AATD's liver manifestations, with plans for a Phase 3 study on the horizon. The collaboration has received Breakthrough Therapy and Orphan Drug designations from the FDA.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.59%
Tags
-
Rhea-AI Summary

Takeda has signed a 15-year lease with BioMed Realty for 600,000 square feet of R&D and office space in Kendall Square, Massachusetts. The new facility will enhance Takeda's research capabilities and support the company's shift towards flexible workspaces. Construction is set to begin in 2023, with occupation expected by 2026. This move aligns with Takeda's goal of achieving net-zero greenhouse gas emissions and reflects its commitment to innovation and sustainability while expanding its presence in a prominent life sciences hub.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.17%
Tags
none
Rhea-AI Summary

Takeda's dengue vaccine candidate TAK-003 has demonstrated significant efficacy, preventing 84% of hospitalizations and 61% of symptomatic dengue cases over 4.5 years. The results from the Phase 3 Tetravalent Immunization against Dengue Efficacy Study (TIDES) indicate no important safety risks. TAK-003 is currently under regulatory review for potential licensure in the European Union and select dengue-endemic countries. The study, involving over 20,000 children and adolescents, aims to address the urgent need for effective dengue prevention.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.22%
Tags
-
Rhea-AI Summary

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) will present significant oncology data at the ASCO and EHA congresses in June. Key highlights include positive Phase 3 PARADIGM study results involving colorectal cancer in Japanese patients and survival data from the Phase 3 ECHELON-1 trial on Hodgkin lymphoma. Additionally, Takeda will showcase advancements in its pipeline targeting innate immunity for cancer treatment. These presentations reflect Takeda's commitment to improving patient care through innovation and collaboration in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
none
-
Rhea-AI Summary

Moderna has announced that it will assume the role of marketing authorization holder for its COVID-19 vaccine Spikevax™ in Japan starting August 1, 2022. This transition includes taking over all related activities, such as import, regulatory compliance, development, quality assurance, and commercialization. In a collaborative effort, Takeda will continue to provide distribution support during a transitional phase of the national vaccination campaign. Both companies aim to ensure smooth operational implementation during this handover.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
covid-19
Rhea-AI Summary

Moderna announces it will take over as the marketing authorization holder for its COVID-19 vaccine, SpikevaxTM, in Japan starting August 1, 2022. This transition from Takeda includes responsibilities for import, local regulations, development, quality assurance, and commercialization. Takeda will continue to provide distribution support during a transitional period. This move aims to strengthen Moderna's commercial organization in Japan as it continues to combat the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.44%
Tags
covid-19
-
Rhea-AI Summary

Takeda Pharmaceutical and Seagen announced that their Phase 3 ECHELON-1 trial for ADCETRIS (brentuximab vedotin) achieved key survival metrics in patients with advanced Hodgkin lymphoma. Data showed a 41% reduction in the risk of death compared to standard treatment ABVD, with a 93.9% six-year overall survival rate for the ADCETRIS combination. The results will be presented at the ASCO and EHA Annual Meetings. The safety profile of ADCETRIS remained consistent with prior studies, showing no new safety signals. This trial marks a significant advancement in treatment options for advanced-stage Hodgkin lymphoma patients.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none
-
Rhea-AI Summary

Takeda reported strong FY2021 results, achieving an underlying revenue growth of 7.4% and a reported revenue increase of 11.6%. Key highlights include a robust free cash flow of JPY 943.7 billion ($7.8B) and significant product approvals across regions. FY2022 guidance predicts continued growth with core operating profit expected to reach JPY 1.1 trillion and reported net profit projected to rise by 26.9%. Takeda's innovative pipeline features approximately 40 clinical stage assets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.06%
Tags
none
Rhea-AI Summary

Summary not available.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.65%
Tags
none

FAQ

What is the current stock price of Takeda Pharmaceutical (TAK)?

Takeda Pharmaceutical (TAK) last closed at $21.77.

What is the market cap of Takeda Pharmaceutical (TAK)?

The market cap of Takeda Pharmaceutical (TAK) is approximately $69.6B.